Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial

Matthew Smith, Karim Fizazi, Teuvo Tammela, Cruz Felipe Melo, Luke T. Nordquist, Diana Sofia Aleman Polanco, Urban Emmenegger, Glauco Costa Silveira, Raoul S. Concepcion, Adriano Paula, Carlos Augusto de Mendonça Beato, Neil E. Fleshner, Martin Eduardo Richardet, Iris Kuss, Marie-Aude Le Berre, Gustavo Borghesi, Toni Sarapohja, Neal Shore

Research output: Other conference contributionAbstractScientific

Original languageEnglish
DOIs
Publication statusPublished - 2021
Publication typeNot Eligible

Cite this